MedTrace Logo

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

NCT00830973 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2009-10-14

No results posted yet for this study

Summary

This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.

Conditions

  • Breast Neoplasms
  • Tamoxifen

Interventions

OTHER

Poor Metabolism Status Follow Up Therapy Considerations

If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.

OTHER

CYP2D6 Inhibiting Drugs

If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.

Sponsors & Collaborators

  • Laboratory Corporation of America

    collaborator INDUSTRY

  • International Business Machines (IBM)

    collaborator INDUSTRY

  • Indiana University School of Medicine

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • Medco Health Solutions, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Epstein, MD, MS · Medco Health Solutions, Inc.

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830973 on ClinicalTrials.gov